E. Bardin

Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches

P. Freemont, S. Faust, J. Bundy, 2016, Expert review of respiratory medicine.

Metabolic Phenotyping and Strain Characterisation of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients Using Rapid Evaporative Ionisation Mass Spectrometry

A. Bush, Z. Takáts, F. Bolt, 2018, Scientific Reports.

"Il faut continuer à poser des questions" patient reported outcome measures in cystic fibrosis: An anthropological perspective.

P. Burgel, I. Sermet-Gaudelus, J. Bend, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A novel application of nylon membranes for tributyltin determination in complex environmental samples by fluorescence spectroscopy and multivariate calibration

G. M. Escandar, A. Olivieri, W. Quiroz, 2015 .

Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis

P. Freemont, S. Faust, J. Bundy, 2017, FEMS microbiology letters.

Modulators of CFTR. Updates on clinical development and future directions.

I. Sermet-Gaudelus, M. Semeraro, C. Gravier-Pelletier, 2021, European journal of medicinal chemistry.

Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches

P. Freemont, S. Faust, J. Bundy, 2016, Expert review of respiratory medicine.

A benchmark study of data normalisation methods for PTR-TOF-MS exhaled breath metabolomics

S. Grassin-Delyle, E. Bardin, E. Lamy, 2023, bioRxiv.

Enhanced real-time mass spectrometry breath analysis for the diagnosis of COVID-19

P. Devillier, E. Naline, S. Grassin-Delyle, 2023, ERJ Open Research.

Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: an open-label proof-of-concept study

S. Grassin-Delyle, H. Salvator, E. Bardin, 2024, medRxiv.